B
BlueWind Medical
Biotech & Life Sciences · Herzliya, Israel · Founded 2010
Evelops and markets an innovative wireless neuro-stimulation device for the treatment of peripheral neuropathic pain MoreLess
BlueWind Medical is a healthcare startup that offers a revolutionary treatment for Urge Urinary Incontinence (UUI), a condition characterized by urgent bladder leaks. The company's flagship product, Revi, is a miniature device implanted near the ankle. This device sends signals to the bladder via nerves, helping manage UUI symptoms.
The company primarily serves patients suffering from UUI, a widespread condition that can significantly impact quality of life. The market for such a solution is substantial, given the prevalence of UUI and the lack of effective long-term treatments.
BlueWind Medical operates on a business-to-consumer model, selling its product directly to patients through healthcare providers. The company generates revenue from the sale of the Revi device and potentially from follow-up services related to the device's adjustment and maintenance.
Revi has shown promising results in clinical studies, with 8 out of 10 participants experiencing a reduction in leaks after one year. The device is implanted in a single outpatient procedure under local anesthesia, making it a convenient and less invasive treatment option.
In summary, BlueWind Medical is a promising startup offering a novel, effective, and convenient solution for UUI, a condition that affects a significant portion of the population.
Keywords: BlueWind Medical, Urge Urinary Incontinence, Revi, bladder control, healthcare startup, outpatient procedure, patient satisfaction, clinical studies, convenient treatment, revenue generation.
Company overview
BlueWind Medical company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2010
- Headquarters
- Herzliya, Israel
- Employees
- 93
- Open positions
- 3
- Dealroom signal
- 66.4
Valuation & funding
BlueWind Medical funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | May 2026 | $24M | — | Undisclosed | ↗ |
| LATE VCOther financing | May 2026 | $24M | $320M | Undisclosed | ↗ |
| SERIES BOther financing | May 2022 | $64M | $256M | ConvaTec | ↗ |
| DEBTDebt | Jan 2022 | $0 | — | Armentum Partners | ↗ |
Growth signals
BlueWind Medical website traffic
Latest recorded traffic for BlueWind Medical is 2.4K monthly website visits, down 17.2% over the last three months. BlueWind Medical's team declined 6.1% over the past year.
Hiring
Open positions at BlueWind Medical
Current openings linked to this company in Dealroom.
Comparisons
BlueWind Medical compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
BlueWind Medical's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on BlueWind Medical's cap table
Sourced from Dealroom's funding and investor records.


Global footprint
Where BlueWind Medical has talent and traffic
team presence
In the news
Latest news about BlueWind Medical
Recent press, funding announcements, and product moves mentioning BlueWind Medical — open to read from the original sources.
Market sentiment
What the market is saying about BlueWind Medical
An AI-synthesized read of the highest-engagement posts about BlueWind Medical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BlueWind Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







